Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved
Rev Saude Publica. 2019 Aug 19:53:68.
doi: 10.11606/s1518-8787.2019053000879.
[Article in
English,
Portuguese]
Affiliations
- 1 Universidade Federal de Minas Gerais. Faculdade de Farmácia. Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica. Belo Horizonte, MG, Brasil.
- 2 McGill University. Division of Clinical Epidemiology. Department of Epidemiology. Montreal, Quebec, Canada.
- 3 Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Farmácia Social. Belo Horizonte, MG, Brasil.
- 4 Universidade Federal de Viçosa. Centro de Ciências Biológicas e da Saúde. Departamento de Nutrição e Saúde. Viçosa, MG, Brasil.
Abstract
Objective:
To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials.
Methods:
A historical cohort study of medical records of adult patients admitted to a general and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted in the period before the restrictive measure for the commercialization of antimicrobials (Phase I) and a second cohort was formed with patients admitted after the implementation of the restrictive measure (Phase II).
Results:
The instantaneous risk of hospital infection by a resistant microorganism was estimated at seven by 1,000 people-time (95%CI 0.006-0.008) in Phase I, and four by 1,000 people-time (95%CI 0.003-0.005) in Phase II of the study. The differences between the survival curves in the different phases of the study and stratified by age group were also significant (p < 0.05).
Conclusions:
The results suggest that the implementation of the restrictive measure of the commercialization of antimicrobials by the National Health Surveillance Agency reduced the incidence of hospital infection by a resistant microorganism.
MeSH terms
-
Anti-Bacterial Agents / administration & dosage*
-
Brazil
-
Cohort Studies
-
Cross Infection / drug therapy*
-
Cross Infection / prevention & control*
-
Drug Monitoring
-
Drug Resistance, Microbial*
-
Drug Utilization / legislation & jurisprudence
-
Female
-
Humans
-
Infection Control / methods
-
Male
-
Middle Aged
-
Prescription Drug Overuse / adverse effects
-
Prescription Drug Overuse / legislation & jurisprudence*
-
Prescription Drug Overuse / statistics & numerical data
-
beta-Lactamases / drug effects
Substances
-
Anti-Bacterial Agents
-
beta-Lactamases
Grants and funding
Funding: Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG - Process APQ-01651-11).